TrademarkDir
INDUS PHARMACEUTICALS
LIVE

Serial Number

78596173

Owner

IndUS Pharmaceuticals, Inc.

Attorney

H. Straat Tenney

First Use Date

Mar 31, 2006

Filing Date

Mar 28, 2005

Add to watchlist:

No watchlists yet
+ Create New Watchlist
View on USPTO

INDUS PHARMACEUTICALS Trademark

Serial Number: 78596173 • Registration: 3674488

INDUS PHARMACEUTICALS is a trademark filed by IndUS Pharmaceuticals, Inc. on March 28, 2005. The trademark is classified under Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

IndUS Pharmaceuticals, Inc. (2 trademarks)

27 Jenkins Road
Andover, MA 01810

Entity Type: 03

Trademark Details

Filing Date

March 28, 2005

Registration Date

August 25, 2009

First Use Anywhere

March 31, 2006

First Use in Commerce

March 31, 2006

Published for Opposition

March 21, 2006

Goods & Services

pharmaceutical drug development services of pharmaceutical products intended for the treatment of infectious diseases, namely, bacterial, fungal, parasitic and viral infections; pharmaceutical drug development services of pharmaceutical products intended for the treatment of neoplastic disorders, namely, hematologic cancer disorders and solid tumors; pharmaceutical drug development services of pharmaceutical products intended for the treatment of autoimmune disorders, namely, diabetes, arthritis, psoriasis, bone marrow and organ transplantation and immunosuppression; pharmaceutical drug development services of pharmaceutical products intended for the treatment of metabolic disorders, namely, obesity and atherosclerosis; pharmaceutical drug development services of pharmaceutical products intended for the treatment of cardiovascular disorders, namely, hypertension, congestive heart failure, myocardial infarction, angina and vascular diseases; pharmaceutical drug development services of pharmaceutical products intended for the treatment of renal disorders, namely, acute and chronic renal failure and urinary disorders affecting renal conservation of water; pharmaceutical drug development services of pharmaceutical products intended for the treatment of central nervous system disorders, namely, analgesia, anesthesia, hypnotics, sedatives, anxiety, psychosis, depression, mania, epilepsies, migraine, neurodegeneration, and drug addiction; pharmaceutical drug development services of pharmaceutical products intended for the treatment of inflammatory disorders, namely, asthma, gout, inflammatory bowel disease, and rheumatoid arthritis; pharmaceutical drug development services of pharmaceutical products intended for the treatment of gastrointestinal disorders, namely, ulcers, emesis, diarrhea, and irritable bowel syndrome; pharmaceutical drug development services of pharmaceutical products intended for the treatment of hormonal disorders affecting the thyroid, estrogens, progestins, androgens, glucocorticoids, insulin and glucose regulation; pharmaceutical drug development services of pharmaceutical products intended for the treatment of calcification and bone turnover; and pharmaceutical drug development services of pharmaceutical products intended for the treatment of dermatological and opthalmological disorders

Filing History

NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
Oct 3, 2019 NA89
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
Oct 3, 2019 RNL1
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
Oct 3, 2019 89AG
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Oct 3, 2019 APRE
TEAS SECTION 8 & 9 RECEIVED
Aug 23, 2019 E89R
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Aug 25, 2018 REM2
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jan 22, 2016 TCCA
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Sep 25, 2015 NA85
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Sep 25, 2015 C15A
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Sep 25, 2015 APRE
TEAS SECTION 8 & 15 RECEIVED
Aug 21, 2015 E815
REGISTERED-PRINCIPAL REGISTER
Aug 25, 2009 R.PR
LAW OFFICE REGISTRATION REVIEW COMPLETED
Jul 21, 2009 REGV
ASSIGNED TO LIE
Jul 21, 2009 ALIE
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Jul 13, 2009 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Jul 9, 2009 SUPC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Jul 9, 2009 AITU
TEAS STATEMENT OF USE RECEIVED
Jun 15, 2009 EISU
USE AMENDMENT FILED
Jun 13, 2009 IUAF
SOU EXTENSION 5 GRANTED
Dec 10, 2008 EX5G
SOU EXTENSION 5 FILED
Dec 10, 2008 EXT5
SOU TEAS EXTENSION RECEIVED
Dec 10, 2008 EEXT
SOU EXTENSION 4 GRANTED
Jun 12, 2008 EX4G
SOU EXTENSION 4 FILED
Jun 12, 2008 EXT4
SOU TEAS EXTENSION RECEIVED
Jun 12, 2008 EEXT
ASSIGNED TO EXAMINER
Jan 8, 2008 DOCK
SOU EXTENSION 3 GRANTED
Dec 13, 2007 EX3G
SOU EXTENSION 3 FILED
Dec 13, 2007 EXT3
SOU TEAS EXTENSION RECEIVED
Dec 13, 2007 EEXT
SOU EXTENSION 2 GRANTED
Jun 13, 2007 EX2G
SOU EXTENSION 2 FILED
Jun 13, 2007 EXT2
SOU TEAS EXTENSION RECEIVED
Jun 13, 2007 EEXT
SOU EXTENSION 1 GRANTED
Dec 13, 2006 EX1G
SOU EXTENSION 1 FILED
Dec 13, 2006 EXT1
SOU TEAS EXTENSION RECEIVED
Dec 13, 2006 EEXT
NOA MAILED - SOU REQUIRED FROM APPLICANT
Jun 13, 2006 NOAM
PUBLISHED FOR OPPOSITION
Mar 21, 2006 PUBO
NOTICE OF PUBLICATION
Mar 1, 2006 NPUB
LAW OFFICE PUBLICATION REVIEW COMPLETED
Feb 3, 2006 PREV
ASSIGNED TO LIE
Dec 2, 2005 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 29, 2005 CNSA
EXAMINERS AMENDMENT E-MAILED
Nov 29, 2005 GNEA
EXAMINERS AMENDMENT -WRITTEN
Nov 29, 2005 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 23, 2005 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 17, 2005 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 17, 2005 TROA
EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
Oct 25, 2005 GEAP
EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED
Oct 25, 2005 CPEA
ASSIGNED TO EXAMINER
Oct 22, 2005 DOCK
NEW APPLICATION ENTERED
Apr 1, 2005 NWAP

Related Trademarks

More from this Owner

SINDU PHARMACEUTICALS

SINDU PHARMACEUTICALS

SINDU PHARMACEUTICALS

SINDU PHARMACEUTICALS